您当前所在的位置:首页 > 产品中心 > 产品信息
Atracurium_分子结构_CAS_64228-79-1)
点击图片或这里关闭

Atracurium

产品号 DB00732 公司名称 DrugBank
CAS号 64228-79-1 公司网站 http://www.ualberta.ca/
分子式 C53H72N2O12++ 电 话 (780) 492-3111
分子量 929.14498 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 613

产品价格信息

请登录

产品别名

标题
Atracurium
IUPAC标准名
1-[(3,4-dimethoxyphenyl)methyl]-2-[3-({5-[(3-{1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium-2-yl}propanoyl)oxy]pentyl}oxy)-3-oxopropyl]-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-2-ium
IUPAC传统名
atracurium

产品登记号

PubChem CID 47319
PubChem SID 46504689
CAS号 64228-79-1

产品性质

溶解度 Miscible

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. [PubChem]
Indication For use, as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Pharmacology Atracurium is a nondepolarizing skeletal muscle relaxant. Atracurium can be used most advantageously if muscle twitch response to peripheral nerve stimulation is monitored to assess degree of muscle relaxation. The duration of neuromuscular block produced by Atracurium is approximately one third to one half the duration of block by d-tubocurarine, metocurine, and pancuronium at initially equipotent doses. As with other nondepolarizing neuromuscular blockers, the time to onset of paralysis decreases and the duration of maximum effect increases with increasing doses of Atracurium. Repeated administration of maintenance doses of Atracurium has no cumulative effect on the duration of neuromuscular block if recovery is allowed to begin prior to repeat dosing. Moreover, the time needed to recover from repeat doses does not change with additional doses. Repeat doses can therefore be administered at relatively regular intervals with predictable results.
Toxicity Excessive doses can be expected to produce enhanced pharmacological effects. Overdosage may increase the risk of histamine release and cardiovascular effects, especially hypotension.
Affected Organisms
Humans and other mammals
Half Life The elimination half-life is approximately 20 minutes.
External Links
Wikipedia
RxList

参考文献